Table 2 Candidate SNP associations with cardiotoxicity in breast cancer patients treated with trastuzumab

7

rs776746

CYP3A5

G

A

0.16

0.38

0.14, 1.00

0.05

15

rs8032978

A

G

0.195

1.79

0.95, 3.41

0.07

2

rs3755319

UGT1A1

A

C

0.429

0.63

0.37, 1.06

0.08

17

rs1058808

ERBB2

C

G

0.409

0.57

0.30, 1.07

0.08

17

rs2643195

ERBB2

A

G

0.375

0.67

0.38, 1.19

0.17

2

rs887829

UGT1A1

C

T

0.321

0.70

0.40, 1.21

0.20

17

rs7406710

C

T

0.150

0.59

0.25, 1.38

0.22

17

rs1136201

ERBB2

A

G

0.189

1.44

0.77, 2.67

0.25

2

rs6759892

UGT1A6

G

T

0.369

0.74

0.43, 1.27

0.27

2

rs7586110

UGT1A7

G

T

0.343

0.82

0.48, 1.39

0.47

13

rs9316695

C

A

0.149

0.81

0.41. 1.60

0.54

17

rs79747793

ERBB2

C

A

0.016

0.54

0.06, 5.20

0.59

4

rs11932853

T

C

0.357

1.16

0.67, 2.02

0.60

17

rs117866580

ERBB2

G

T

0.019

0.58

0.07, 5.13

0.62

17

rs4252633

ERBB2

G

T

0.006

2.07

0.10, 43.7

0.64

13

rs1751034

ABCC4

A

G

0.032

1.37

0.33, 5.70

0.66

17

rs35797841

ERBB2

C

T

0.054

0.83

0.26, 2.61

0.75

11

rs57242572

C

T

0.037

0.76

0.12, 4.79

0.77

6

rs628031

SLC22A1

A

G

0.349

0.92

0.52, 1.63

0.79

15

rs28415722

G

A

0.392

1.06

0.65, 1.75

0.81

11

rs61918162

T

C

0.293

1.04

0.60, 1.81

0.88